There are a number of different antibody therapeutic modalities the industry is working on - from mAbs, to bispecifics, to ADCs - increasingly exploring new non-cancer targets. Each therapeutic type and target brings its own set of challenges, opportunities and strategies, as well as corresponding technologies and platforms.
The Antibody Engineering & Therapeutics conference series is conducting a survey of industry professionals from around the world. The final report will reveal unique insights into the hottest potential opportunities and the biggest challenges around antibody therapeutic modalities and targets.
Click here to take part in the survey.
Completing the survey will take just 5 minutes and will give you exclusive early access to the final report. All answers will remain anonymous. Plus, everyone who completes the survey by Sunday 17th May 2020 will be entered into a prize draw for a free conference pass to their choice of Informa Connect Antibody Engineering & Therapeutics conference (full terms and conditions can be found here):
- 4 day pass: Antibody Engineering & Therapeutics - 13-17 December 2020, San Diego, CA
- 3 day pass: Antibody Engineering & Therapeutics Asia - 24-26 February 2021, Kyoto, Japan
- 2 day pass: Antibody Engineering & Therapeutics Europe – 25-27 August 2020, Amsterdam, The Netherlands
We’re excited to see the results of this study and we hope you are too.